Pulmonary rehabilitation, physical activity and aortic stiffness in COPD by Aldabayan, YS et al.
RESEARCH Open Access
Pulmonary rehabilitation, physical activity
and aortic stiffness in COPD
Yousef S. Aldabayan1, Heidi A. Ridsdale2, Ahmed M. Alrajeh1, Abdulelah M. Aldhahir1, Arthur Lemson3,
Jaber S. Alqahtani1, Jeremy S. Brown1 and John R. Hurst1*
Abstract
Background: Patients with chronic obstructive pulmonary disease (COPD) have elevated cardiovascular risk, and
cardiovascular disease is a major cause of death in COPD. The current literature indicates that changes in
cardiovascular risk during pulmonary rehabilitation (assessed using aortic stiffness) are heterogeneous suggesting
that there may be sub-groups of patients who do and do not benefit.
Objectives: To investigate the characteristics of COPD patients who do and do not experience aortic stiffness
reduction during pulmonary rehabilitation, examine how changes relate to physical activity and exercise capacity,
and assess whether changes in aortic stiffness are maintained at 6 weeks following rehabilitation.
Methods: We prospectively measured arterial stiffness (aortic pulse-wave velocity), exercise capacity (Incremental
Shuttle Walk Test) and physical activity (daily step count) in 92 COPD patients who started a six week pulmonary
rehabilitation programme, 54 of whom completed rehabilitation, and 29 of whom were re-assessed six weeks later.
Results: Whilst on average there was no influence of pulmonary rehabilitation on aortic stiffness (pre- vs. post
pulse-wave velocity 11.3 vs. 11.1 m/s p = 0.34), 56% patients responded with a significant reduction in aortic
stiffness. Change in aortic stiffness (absolute and/or percentage) during rehabilitation was associated with both
increased physical activity (rho = − 0.30, p = 0.042) and change in exercise capacity (rho = − 0.32, p = 0.02), but in
multivariable analysis most closely with physical activity. 92% of the responders who attended maintained this
response six weeks later.
Conclusion: Elevated aortic stiffness in COPD is potentially modifiable in a subgroup of patients during pulmonary
rehabilitation and is associated with increased physical activity.
Trial registration: ClinicalTrials.gov Identifier: NCT03003208. Registered 26/12/ 2016.
Keywords: COPD, Aortic stiffness, And pulmonary rehabilitation
Background
Chronic obstructive pulmonary disease (COPD) is a lead-
ing cause of global morbidity and mortality [1]. Patients
with COPD have more co-morbidity than smoking-
matched controls [2], including a 2–5 fold greater risk of
cardiovascular (CV) disease [3]. CV diseases are a major
cause of death in COPD [4]. As reported by the World
Health Organisation, COPD will be the third most com-
mon cause of death by 2030 if no new interventions are
put in place [5], and reducing mortality in COPD requires
health-care professionals to take an holistic approach.
Early detection and prediction of cardiovascular (CV) risk
is therefore critical in people with COPD [4]. Arterial stiff-
ness assessed by aortic Pulse Wave Velocity (aPWV) is
recognised as a gold-standard biomarker of increased CV
risk in COPD, as it is in healthy populations [6–8]. Ele-
vated arterial stiffness occurs as a consequence of bio-
logical aging and atherosclerosis which may lead to
increased risk of cardiovascular mortality [9]. It has been
consistently reported that the main contributing factors
relating to increased arterial stiffness are hypertension,
metabolic disorders and chronic inflammation [10] all of
which are commonly present in COPD [11]. Therefore,
reducing aortic stiffness may lower the risk of future CVD
which is a major cause of death in COPD. However, it
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remains un-known whether increased aortic stiffness in
COPD is modifiable [12, 13]. We have previously re-
ported that CV risk in COPD is stable over time, but
elevated at exacerbations [14].
It is known that physical activity (PA) reduces CV risk.
In coronary artery disease, exercise programmes reduce
aPWV [15]. Reduced physical activity is common in
COPD [16, 17]. Pulmonary Rehabilitation (PR), a group
exercise and education programme is an evidence-based
intervention in COPD to reduce symptoms, improve ex-
ercise performance, reduce exacerbations and improve
health-status [18–21]. We have previously reviewed the
literature on the effect of PR on aortic stiffness in COPD
[22]. Whilst the large and well-conducted study by Van-
fleteren reported that, on average, there was no influence
of PR on arterial stiffness in COPD, the data suggest that
arterial stiffness responses to PR were highly heteroge-
neous such that there may have been sub-groups of
patients who did and did not benefit. Previous work has
not examined the relationship between physical activity,
PR outcomes and aortic stiffness in COPD. We hypothe-
sised that patients who had the greatest physical activity,
and the greatest improvement in exercise capacity
during PR would be those that experienced the greatest
aortic stiffness reduction. This study aimed to investigate
the characteristics of COPD patients who do and do not
experience aortic stiffness reduction during PR. We also
wanted to examine how changes in aPWV relate to
physical activity and exercise capacity and assess
whether changes in aortic stiffness during PR were
sustainable 6 weeks after the end of the class.
Method
Participants
We approached 106 consecutive patients enrolling on the
Central and North West London NHS Foundation Trust
PR classes held at the Peckwater Center, and St. Pancras
Hospital in London, UK. A total of 102 (58 male, 44 fe-
male) with a confirmed diagnosis of COPD (post-bron-
chodilator FEV1/ FVC < 0.70 and appropriate exposure
history) were recruited (Fig. 1; only two patients refused
to take part). Participants referred to PR were scheduled
for an assessment visit before the first class, performed by
registered physiotherapists. In patients agreeing to take
part, a full medical history including cardiovascular risk
and co-morbidities was documented during this assess-
ment visit. Of 102 participants, 54 completed PR with
complete pre- and post-measurements and this group
comprised the main analysis.
Pulmonary rehabilitation
The PR course consisted of sessions two hours long,
twice each week for six weeks. The PR programme is
based on British Thoracic Society (BTS) PR guidelines
[23]. The first hour comprised an exercise component to
both lower and upper limbs supervised by respiratory
physiotherapists. It included low resistance training exer-
cises such as free weights, and therabands. It also in-
cluded aerobic exercises such as treadmill, walking, and
cycling. The intensity of the workout was individualised
based on the condition of each participant. Physiothera-
pists encouraged the participants to exercise for a mini-
mum of 10min on each exercise at level 3 to 4 on the
Borg scale. The second hour consisted of education
which was delivered by a multidisciplinary team includ-
ing nurses, physiotherapists, doctors, psychologists,
dietitians, and occupational therapists.
Fig. 1 Consort diagram
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Measurements
Comprehensive data were gathered from each partici-
pant including demographic and clinical information.
COPD exacerbation frequency was defined as the num-
ber of events treated with oral antibiotics and or cortico-
steroids in the previous year. Breathlessness, quality of
life, and anxiety & depression were assessed using CAT
COPD [24], MRC dyspnoea [25] and HADS [26]
questionnaires respectively. Aortic stiffness was directly
measured by arterial pulse wave velocity (aPWV; further
detail below) and calculated using QRISK2 to estimate
the risk of having a heart attack or stroke over the next
ten years [27].
The following measurements were made at the start
and end of PR, and the duration between these times
and number of classes attended were recorded.
Arterial stiffness measurements (aPWV)
Arterial stiffness was determined by measuring aPWV
between the carotid and femoral arteries using Vicorder
(Skidmore Medical, Bristol, UK) equipment. Based on
the manufacturer’s instructions, the participant was
asked to lie at 45°. Then, both of the carotid and femoral
cuffs were attached. The carotid cuff was positioned over
the carotid palpation area and the femoral cuff was posi-
tioned around the upper right thigh. Next, the partici-
pant lay supine to measure the distance between the
suprasternal notch and each of the femoral and carotid
arteries. After the distance was recorded, the bed was
raised back to 45° to start the aPWV measurement,
expressed in meters per second. After 10 min rest, one
aPWV set was measured for each participant (three
readings a set). The mean of those measures was used.
We have previously reported that aPWV is stable over
time in patients with COPD [14] and thus any changes
that we see during PR can likely be attributed to the PR
intervention.
Spirometry measurements (FEV1, FVC and FEV1/FVC)
Participants were referred to PR with spirometry re-
sults confirming COPD. However, to ensure contem-
poraneous lung function results, we performed post-
bronchodilator hand-held spirometry using a Micro 1
Handheld Spirometer (CareFusion, Basingstoke, UK)
which conform to the requirements of the ATS/ERS
standards [28] and these values were used for ana-
lysis. The participants were seated during this test.
Measurements were made in triplicate to published
quality-assurance criteria [29].
Exercise capacity: incremental shuttle walking test (ISWT)
The ISWT was conducted in accordance to the ERS/
ATS guidelines [30]. Participants were instructed in how
to perform the test. Two cones were placed a distance of
9 m apart. Next, a pre-recorded CD played a dictated
tempo from a metronome such that walking speed was
externally paced. The number of laps and time given are
divided into 12 levels, each level containing an additional
lap compared to the previous one and the shortened
time between laps requires increased walking speed.
Heart rate, oxygen saturation and dyspnea (Borg scale)
were measured prior to and directly after the test. These
outcomes were re-measured 1 and 2min after recovery.
The walking test was terminated when the patient was
unable complete a full shuttle within the time frame
allowed. To counteract a possible learning effect and
ensure a maximal result on the ISWT, we conducted a
second ISWT. The test showing the higher distance was
used in the analysis.
Physical activity monitoring
We asked participants to wear a step counter pedometer
on their waist all the time whether inside or outside the
PR class (except when sleeping and showering) and to
record the total daily physical activity on a diary card.
This was for the six-week duration of the class and for
the subsequent six-weeks after PR completion. We used
a Yamax SW-200 electronic pedometer, which has
previously been shown to be a reliable and valid device
[31–33]. One week after the start of PR we contacted
patients to make sure that they were able to use and rec-
ord data from the step counter.
Follow-up
Participants who completed the PR programme were
asked to attend again six weeks after the end of PR for
re-evaluation. Exercise was not supervised during this
period; however, physical activity was monitored by
providing a step counter pedometer. At the end of the
six weeks, patients were re-assessed, completing the
same evaluations described above.
Statistical analysis
Data were assessed using histograms and tested for nor-
mality using the Kolmogorov–Smirnov test. Data are
expressed as mean (SD) for normally distributed data or
median (IQR) for non-normally distributed data as
appropriate. We examined the change in aPWV pre-
and post-exercise and classified our participants as
responders (reduction of ≥0.5 m/s) or non-responders
(less benefit than this).
To complete a power calculation we contacted the au-
thors of the largest previous study [13], who reported
that 35% of their participants were responders according
to these criteria (≥0.5 m/s reduction). A priori, and as
described in the trial registration, we planned a multivar-
iable analysis on responder status including change in
exercise capacity (change in ISWT pre- and post),
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physical activity (mean of steps/day) with or without
inclusion of one other variable decided on the basis of
significance in simple correlation analysis. This required
us to have 30 responders. For other comparisons, paired
t-tests were used for parametric data, and Wilcoxon
signed-rank testing was used for non-parametric paired
data. Relationships were analysed using Pearson correl-
ation for normally distributed data, and Spearman rank
correlation for non-parametric data. Data was analysed
using Statistical Package for the Social Sciences (SPSS),
Version 21.
Results
Baseline characteristics of the patients
We approached 106 consecutive patients enrolling on
two PR programmes in Camden, London, UK and 104
agreed to take part. Spirometry did not confirm COPD
in two of these. The CONSORT diagram is illustrated as
Fig. 1. Ultimately, 92 patients started and 54 patients
completed PR within 6–10 weeks of starting (termed
“completers” and this group forms the main analysis).
The characteristics of these 54 patients are provided in
Table 1, which shows they had a mean age of 73 years,
63% were male and the mean FEV1 was 1.23 L (50% pre-
dicted). Table 1 also provides information on the 102
total population, and compares the 54 completers with
the 48 non-completers (who attended the assessment
visit but did not start, or complete PR within the desig-
nated time). The dropout rate during PR was 36%. The
completers were generally similar to the non-completers
in age and sex, but tended to have more severe COPD
and greater baseline aortic stiffness.
Effectiveness of PR
First, we wanted to confirm that the PR programme met
standard goals. In the 54 completers there was a signifi-
cant improvement from baseline to completion in mean
(SD) ISWT (254.3 ± 118.4 vs. 305.1 ± 115.0m, p < 0.001),
CAT questionnaire (18.7 ± 6.7 vs. 16.4 ± 6.7, p < 0.01) and
mMRC dyspnoea score (3(2–4) vs. 3(2–3), p < 0.001).
Primary analysis
As expected, we did not see an overall difference in aor-
tic stiffness in response to PR (Table 2; Fig. 2). There
was a trend to an overall reduction in systolic and mean
arterial blood pressure, that was not statistically signifi-
cant but at a clinically meaningful level (> 3 mmHg).
As previously reported by Vanfleteren [13], we did
identify a group of individuals who experienced a clinic-
ally significant change in aPWV in response to PR. Of
the 54 patients, 30 (56%) had a significant response
(defined as a reduction of 0.5 m/s or greater) and 24 had
no clinically significant improvement.
As described above, in our a priori statistical plan, we
had elected to perform a multi-variable analysis includ-
ing change in ISWT, average step count over the
duration of the PR class, and the possibility of a third
variable chosen if simple correlation of other variables
against change in PWV proved to be statistically signifi-
cant. However, in simple correlation analysis, we did not
identify any other factors associated with change in
PWV after PR (Table 3). The step count data during PR
is included in Table 4.
Next, we went on to explore the relationship between
change in aPWV and the two variables we had specific-
ally intended to examine: change in exercise capacity
(assessed by ISWT) and physical activity (assessed using
average step count).
Change in aPWV related to both change in exercise
capacity and to physical activity. In simple correlation
analysis, there was a significant association between
larger reduction in aPWV and greater change in ISWT
(rho = − 0.32, p = 0.020, Fig. 3a) and, when expressed as
percentage change, there was a significant association
between greater reduction in PWV and higher physical
activity (rho = − 0.30, p = 0.042, Fig. 3b).
We noted that the starting blood pressure was higher
in the responders than the non-responders (103.61 ±
12.55 vs. 95.90 ± 12.44 mmHg, p = 0.03) and that a
greater proportion of the non-responders were already
prescribed anti-hypertensive medication (81% vs. 39%,
p = 0.02). The blood pressure in the responders reduced
by a clinically and statistically significant degree: the
mean fall in systolic BP was 6.30 mmHg (p = 0.043), dia-
stolic BP was 4.94 mmHg (p = 0.041) and mean arterial
pressure was 5.39 mmHg (p = 0.020). There were no
alterations in any of the participant’s medications during
the rehabilitation programme.
We performed multivariable regression analysis to bet-
ter understand the relationship between physical activity,
exercise capacity and change in aortic stiffness during
PR. For every 1000 additional steps walked during PR,
adjusted for baseline aPWV, aPWV decreased by 0.2 m/s
(95%CI, 0.4 to 0.0 m/s change, p = 0.03). There was not
an independent effect of change in exercise capacity on
pulse wave reduction (p = 0.19).
Follow-up
Next we wanted to assess whether changes in aortic
stiffness, exercise capacity and physical activity were
maintained six weeks after the end of the PR class. The
results for the 29/54 patients in whom these data were
available are presented in Table 4. There were no overall
differences in PWV or exercise capacity comparing the
end of PR with six weeks later, or average physical
activity during PR compared to physical activity in the
following six weeks.
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Table 1 Baseline characteristics of subjects with chronic obstructive pulmonary disease (COPD) referred to PR and consented for the
study, divided into those who did and did not complete PR
Subjects Demographics Total population (102) Completed PR (54) Not completed (48) p-value
Age (years) 71.31 ± 9.06 72.71 ± 8.48 69.71 ± 9.54 0.10
Male 59 (58%) 34 (63%) 25 (52%) 0.27
Female 43 (42%) 20 (37%) 23 (48%)
Active smoker 30 (29%) 12 (22%) 18 (37%) 0.09
Ex-smokers 72 (71%) 42 (78%) 30 (63%)
Smoking history (pack-years) 45 (27–63) 47 (23–60) 44 (31–66) 0.49
Body composition
Body Mass Index (kg/m2) 26.70 ± 6.09 26.47 ± 6.13 26.99 ± 6.10 0.67
Pulmonary function
FEV1 (L) 1.26 ± .41 1.23 ± 0.41 1.51 ± 0.58 0.01
FEV1 (% predicted) 50.69 ± 16.29 50.47 ± 17.55 60.29 ± 19.39 0.01
FEV1/FVC % 47.51 ± 11.88 49.20 ± 12.28 58.07 ± 10.93 < 0.01
Haemodynamic
Aortic pulse wave velocity (m/s) 10.84 ± 2.29 11.34 ± 2.33 10.05 ± 2.03 0.01
Systolic pressure (mmHg) 138.75 ± 18.33 139.91 ± 19.04 137.29 ± 17.76 0.47
Diastolic pressure (mmHg) 80.15 ± 13.48 80.38 ± 14.13 79.98 ± 12.97 0.91
Mean arterial pressure (mmHg) 98.68 ± 15.94 100.19 ± 12.98 96.93 ± 18.85 0.31
Pulse pressure (mmHg) 77.70 ± 14.59 76.94 ± 16.91 78.73 ± 11.545 0.52
Functional outcomes (pre-PR)
ISWT (m) 254.32 ± 118.41 254.1 ± 116.6 254.6 ± 122.1 0.98
mMRC grade 3 (2–4) 3 (2–4) 3 (2–4) 0.65
CAT 19.96 ± 8.06 18.72 ± 6.72 21.56 ± 8.78 0.08
Anxiety scores (HADS) 5 (2–7) 5 (2–7) 6 (3–11) 0.06
Depression scores (HADS) 5 (2–6) 5 (2–6) 6 (4–8) 0.06
CV risks determinants
Diabetes Yes: 18 (18%) Yes: 7 (13%) Yes: 9 (19%) 0.37
Hypertension Yes: 54 (54%) Yes: 29 (46%) Yes: 25 (52%) 0.56
Hyperlipidaemia Yes: 44 (43%) Yes: 24 (44%) Yes: 20 (42%) 0.78
Ischemic heart disease Yes: 5 (5%) Yes: 1 (2%) Yes: 4 (8%) a
Myocardial infarction Yes: 4 (4%) Yes: 3 (6%) Yes: 1 (2%) a
Peripheral arterial disease Yes: 7 (7%) Yes: 4 (7%) Yes: 3 (6%) a
Heart failure Yes: 7 (7%) Yes: 2 (4%) Yes: 5 (10%) a
Atrial fibrillation Yes: 13 (12%) Yes: 9 (17%) Yes: 4 (8%) a
Stroke Yes: 10 (10%) Yes: 3 (6%) Yes: 7 (15%) a
Data are presented as mean (SD), median (IQR) or n (%) as appropriate. FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, ISWT incremental shuttle
walk test, mMRC modified Medical Research Council, HADS hospital anxiety and depression score.a too few for comparison
Table 2 Differences in aortic pulse wave velocity and other haemodynamics measures in 54 COPD subjects who completed PR
Haemodynamic measurement Baseline After PR p-value
Aortic pulse wave velocity (m/s) 11.34 ± 2.33 11.14 ± 2.58 0.34
Systolic pressure (mmHg) 139.91 ± 19.04 135.84 ± 14.51 0.09
Diastolic pressure (mmHg) 80.38 ± 14.13 78.91 ± 10.914 0.39
Mean arterial pressure (mmHg) 100.19 ± 12.98 96.07 ± 16.75 0.09
Pulse pressure (mmHg) 76.94 ± 16.91 78.15 ± 12.31 0.62
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We specifically wanted to examine whether those pa-
tients who experienced aortic stiffness reduction with PR
maintained this response at six weeks. The mean aPWV
was not different in the responders from the end of PR to
the six week visit (10.44 vs. 10.16m/s, p = 0.76), and of the
13 people in this group only one patient experienced a
subsequent rise in PWV of ≥0.5m/s. The beneficial aortic
stiffness reduction was therefore maintained in 92% of the
responders who attended. Non-responders included those
who had a change in aPWV within 0.5 m/s of baseline
(the “no change” group) and those who had a > 0.5 m/s in-
crease (the “increased” group) during PR. We subdivided
our non-responders and showed that the “no change”
group maintained similar aortic stiffness (10.79 vs. 10.82
m/s, p = 0.86) and exercise capacity (314 vs. 291m, p =
0.18) at six weeks following PR completion. In contrast,
the six patients who appeared to have an increase in
aPWV during the PR programme showed a significant re-
duction in aPWV at six weeks (13.43 vs. 12.86m/s, p <
0.001), associated with a significant increase in exercise
capacity during this period (208 vs. 235m, p = 0.02), per-
haps suggesting a delayed response to PR in this group.
Finally, we wanted to assess over this second six-
week period whether PA and change in exercise cap-
acity still related to change in aPWV. In simple
correlation analysis aPWV related to both physical ac-
tivity (rho = − 0.55, p = 0.03) and change in exercise
capacity (rho = − 0.61, p < 0.01) suggesting that pa-
tients who maintain activity and gains in exercise
capacity are those who maintain the aortic stiffness
response achieved during PR.
Discussion
We report that elevated aortic stiffness in COPD can be
reduced in 56% of patients through effective pulmonary
rehabilitation, and that this reduction is correlated with
greater physical activity and a reduction in blood pres-
sure. Moreover, in the majority of patients who have a
reduction in aortic stiffness, this improvement in aortic
stiffness reduction is maintained six weeks after the end
of PR. This has not been previously reported: existing
studies indicated that aortic stiffness was not influenced
by PR overall and were not able to identify the charac-
teristics of responder and non-responder groups, and
nor was the durability of the response assessed. Our
results widen the accepted benefits of PR to include
reduction of aortic stiffness, suggesting that PR pro-
grammes should focus on maximising physical activity
outside of the course to achieve holistic benefits, and
demonstrating that elevated aortic stiffness in COPD is
durably modifiable with PR.
Fig. 2 Individual changes in aortic pulse wave velocity (aPWV) before and after pulmonary rehabilitation. Solid line and circles represent the mean
Table 3 Correlation between change in aortic stiffness (aPWV)
after PR with baseline demographic and clinical measures in 54
patients with COPD
Outcomes Mean ± SD, or median
(IQR)
p-value
Age (years) 72.71 ± 8.48 r = − 0.01 0.93
FEV1 (L) 1.23 ± 0.41 r = −0.10 0.47
FEV1 (% predicted) 50.47 ± 17.55 r = −0.09 0.49
FEV1/FVC % 49.20 ± 12.28 r = 0.05 0.71
BMI (kg/m2) 26.47 ± 6.13 r = 0.02 0.85
SBP (mmHg) 139.97 ± 18.87 r = 0.21 0.12
DBP (mmHg) 80.30 ± 14.01 r = 0.11 0.42
MAP (mmHg) 96.07 ± 16.75 r = 0.18 0.19
QRISK% 32.23 ± 16.87 r = −0.02 0.86
Smoking (pack years) 47 (23–60) r = − 0.08 0.56
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56% of patients completing PR in our study had a sig-
nificant reduction in aortic stiffness (defined as a 0.5 m/s
reduction or greater). The responders had a clinically
meaningful and statistically significant reduction in
blood pressure. Change in aPWV was related to both
change in exercise capacity during PR, and to physical
activity outside of the class. Multivariable analysis con-
firmed that physical activity was the more important of
these two factors. Six weeks later, 92% of the re-
sponders who attended maintained this benefit, with
both average physical activity and change in exercise
capacity in the six weeks following PR related to change
in aortic stiffness over this period. Change in aortic stiff-
ness was not restricted to those with or without a previ-
ous history of cardiovascular diseases or recognised
cardiac risk factors. There was no alteration in potential
confounders such as anti-hypertensive medication dur-
ing PR. Our results emphasise the importance of phys-
ical activity on reduction of aortic stiffness in COPD.
We have recently published a systematic review sum-
marising studies examining the effect of PR on CV risk
reduction measured by aPWV in COPD [22]. This iden-
tified three papers. Our results are in keeping with the
largest of these by Vanfleteren [13], a well-conducted
study which found no overall difference in aPWV with
PR, but in which there were a group of patients who
responded. Vanfleteren was not able to identify the rea-
sons for this differential response, but did not measure
physical activity – our major hypothesis. Our response
rate at 56% is higher than the 35% response rate in this
study (personal communication). The two smaller stud-
ies identified in our review [34, 35] both found an over-
all reduction in aortic stiffness with exercise. Vivodtzev
investigated the effect of endurance training on aortic
stiffness in 17 patients with COPD. There was a 10%
reduction in arterial stiffness after exercise endurance in
the trained COPD group [34]. Gale investigated the
impact of pulmonary rehabilitation on reducing aortic
stiffness in COPD. In a study of 32 COPD patients and
20 healthy controls, there was a significant improvement
in aortic stiffness in COPD patients after PR [35]. Since
publication of our original review we have identified one
further study. Moore evaluated the relationships be-
tween exercise capacity, physical activity and cardiovas-
cular risk in COPD patients during PR. Once again,
there was no overall change in arterial stiffness with PR
but by grouping participants into low- and high-exercise
tolerance groups, they reported that the lower exercise
tolerance group had a better CV benefit [36]. Physical
activity was not related to reduction in cardiovascular
risk in this study, but activity was only measured for
three days prior to commencing PR. Importantly, our
study is the only one to measure physical activity during
PR, and the only one to re-assess patients six weeks
following PR to assess if benefits obtained during PR are
maintained.
People with COPD are known to be less active than
healthy controls [37]. Physical inactivity is a major risk
factor for CV disease in general, and a predictor of
mortality in COPD [38]. Reduced physical activity is
associated with increased cardiovascular risk and may
potentially explain the increased prevalence of CV dis-
eases in people with COPD [16]. A systematic review
[17] demonstrated consistent associations between phys-
ical activity, mortality and exacerbations, but found
insufficient evidence to make firm conclusions about the
Fig. 3 Scatter plots demonstrating correlations between absolute ΔaPWV and ΔISWT after completing PR (a – rho = − 0.32, p = 0.020) and
between ΔaPWV% and average PA during the six weeks PR (b – rho = − 0.30, p = 0.042)
Aldabayan et al. Respiratory Research          (2019) 20:166 Page 8 of 11
major determinants of physical activity in COPD. COPD
is often accompanied by hypertension and the American
Heart Association have stated that increasing physical ac-
tivity reduces blood pressure and therefore may reduce
cardiovascular risk [39]. Given the impact of physical ac-
tivity on adverse outcomes in COPD, improving physical
activity should be a key goal of COPD management.
There is little previous information on the relationship
between exercise capacity and aortic stiffness in COPD.
Stickland reported that VO2 max during a cardiopul-
monary exercise testing test was independently associ-
ated with arterial stiffness in COPD subjects without
CVD [37].
In our study, 56% of patients had a beneficial aortic
stiffness response during PR, defined as a reduction of
0.5 m/s or greater in aPWV. Meta-analysis of > 12 000
subjects has demonstrated that a difference of ≥0.5 m/ s
in aPWV corresponds to a 7.5% reduction in CV risk,
such that a 0.5 m/s reduction in aPWV can be consid-
ered clinically meaningful [3]. We therefore selected a
reduction of 0.5 m/s or greater as a clinically meaningful
change in aPWV. Walking an additional 2500 steps was
associated with a reduction of 0.5 m/s in aPWV. How-
ever, walking an additional 2500 steps/day might be a
challenge for patients with more severe COPD.
The question of whether elevated aortic stiffness is
modifiable in COPD is clinically important. Our study
builds on studies suggesting that CV risk in COPD may
be modifiable with respiratory interventions such as
long-acting bronchodilators and inhaled corticosteroids
[40], and not solely require interventions directly target-
ing the CV system.
The strengths of this study include the fact that
patients with and without CV history were approached
sequentially, and therefore that our subjects are repre-
sentative of those attending PR classes in the UK. The
completers were similar to the non-completers, except
that they had slightly elevated aortic stiffness and COPD
severity. All testing was performed to established guide-
lines and quality assurance, and arterial stiffness was
determined by aPWV which is a gold standard method
for measuring arterial stiffness. Our study was ad-
equately powered, with an a priori power calculation
and statistical plan. One of the limitations of our study
is the relatively high dropout rate (36%). However, this is
a recognised problem in pulmonary rehabilitation pro-
grammes and our rate is lower than the UK national
COPD Audit data reporting a 38% dropout rate [41].
The reasons for high attrition rates in PR and how to
mitigate this remain poorly understood and require fur-
ther study. PR in other settings may be of a different,
often longer duration, and this may be a more effective
approach. Similarly, not all participants attended the six
week follow-up appointment after the six week PR. We
measured physical activity using a pedometer. We se-
lected the best available device and deliberately chose
simple, inexpensive equipment such that our results can
be implemented easily in clinical practice. We recognise
that additional information on physical activity and
intensity would have been provided using an accelerom-
eter, and that such equipment does not rely on partici-
pants manually recording and resetting the device on a
daily basis. However, steps are a more intuitive concept
for patients and clinicians to understand than markers
of energy expenditure, and the chosen Yamax pedometer
has been identified as the most reliable and valid device
available [31–33]. Finally, we only assessed the durability
of the response in aortic stiffness out to six weeks post-
PR, and future studies would usefully consider longer
term responses.
A previous study in our department [14] recruiting a
similar cohort (n = 90, age 72.07 ± 9.92 years and FEV1
1.28 ± 0.54 L) monitored aortic stiffness in COPD pa-
tients over time in the absence of PR. In this study the
proportion of participants who had a decrease in aortic
stiffness of > 0.5 m/s was 30% compared to 56% in our
study with the PR intervention. In our current study,
non-responders were defined as those who did not
achieve > 0.5 m/s reduction in aortic stiffness. This in-
cluded those with no change (26%; aPWV remained
within 0.5 m/s of baseline) and those with greater than a
0.5 m/s increase in aortic stiffness. Among the 90
patients in the previous study with no PR intervention,
the proportion of those with an increase of more than
0.5 m/s was 23/90 (26%) compared to 10/54 (18%) of
our participants who attended PR. This indicates a
downward shift in the whole population in aPWV in pa-
tients undergoing PR compared to those assessed over
time with no intervention.
Our results have important implications for clinical
practice. First, they emphasise the value of encouraging
people with COPD to maintain physical activity, and
that encouraging this during PR may be associated with
optimal, holistic benefits from PR in reducing aortic
stiffness. Second, our study increases the evidence base
for PR in that we have shown that PR can reduce aortic
stiffness in a proportion of patients with COPD, likely
through an effect on reducing blood pressure. Import-
antly this benefit was not restricted to those with (or
without) established CV disease, and we provide the first
evidence that a non-pharmacological COPD-targeted
intervention may be able to modify aortic stiffness in
COPD for at least six weeks.
Conclusions
We report that elevated aortic stiffness in COPD is po-
tentially modifiable in a subgroup of patients through
pulmonary rehabilitation and that this reduction is
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related to physical activity. This improvement was main-
tained for at least six weeks following PR. Our results
widen the accepted benefits of PR to include reduc-
tion of aortic stiffness, suggest that PR programmes
should focus on maximising physical activity, and
demonstrate that elevated aortic stiffness in COPD is
modifiable with PR.
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